Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Director William R. Ringo sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $38.00, for a total value of $76,000.00. Following the completion of the sale, the director now owns 2,000 shares in the company, valued at approximately $76,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Five Prime Therapeutics, Inc. (FPRX) opened at 37.59 on Thursday. The stock’s market cap is $1.05 billion. Five Prime Therapeutics, Inc. has a 52-week low of $25.97 and a 52-week high of $60.98. The firm has a 50-day moving average price of $34.11 and a 200 day moving average price of $31.83.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.43). The firm had revenue of $7.80 million for the quarter, compared to analyst estimates of $8.32 million. Five Prime Therapeutics had a negative return on equity of 31.78% and a negative net margin of 356.39%. The business’s revenue for the quarter was down 16.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.49) earnings per share. Analysts expect that Five Prime Therapeutics, Inc. will post ($5.29) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece was originally published by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at http://www.mareainformativa.com/insider-selling-five-prime-therapeutics-inc-fprx-director-sells-76000-00-in-stock/117021/.

A number of hedge funds have recently modified their holdings of FPRX. Renaissance Technologies LLC acquired a new position in Five Prime Therapeutics during the first quarter worth $16,734,000. Marshall Wace North America L.P. acquired a new position in shares of Five Prime Therapeutics in the first quarter worth $10,272,000. MARSHALL WACE ASIA Ltd acquired a new position in shares of Five Prime Therapeutics in the first quarter worth $10,272,000. State Street Corp raised its holdings in shares of Five Prime Therapeutics by 25.7% in the first quarter. State Street Corp now owns 1,249,520 shares of the biotechnology company’s stock worth $45,175,000 after acquiring an additional 255,488 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Five Prime Therapeutics by 162.9% in the second quarter. JPMorgan Chase & Co. now owns 298,395 shares of the biotechnology company’s stock worth $8,984,000 after acquiring an additional 184,888 shares during the last quarter. 84.05% of the stock is owned by hedge funds and other institutional investors.

Several research firms have commented on FPRX. BMO Capital Markets restated a “hold” rating and issued a $39.00 price objective on shares of Five Prime Therapeutics in a research report on Friday, September 22nd. Royal Bank Of Canada began coverage on Five Prime Therapeutics in a research report on Thursday, September 14th. They issued an “outperform” rating and a $41.00 price objective on the stock. Jefferies Group LLC restated a “buy” rating and issued a $52.00 price objective on shares of Five Prime Therapeutics in a research report on Tuesday, September 12th. ValuEngine upgraded Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, BidaskClub lowered Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $57.50.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Insider Buying and Selling by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Stock Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related stocks with our FREE daily email newsletter.